♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
C O P D :State of the Art
1. COPD State-of-the-Art Richard K. Albert, M.D. Chief of Medicine Denver Health Professor of Medicine University of Colorado Adjunct Professor of Engineering and Computer Science University of Denver 8 th Pulmonary Medicine Update February 6, 2008 Denver Health
4. Changes in Definition of COPD ATS/ERS Guidelines COPD has systemic consequences - Systemic inflammation - Weight loss - Skeletal muscles - Cardiac disease and death (Huiart, Chest 2005) > 5648 receiving “1 st Rx for COPD” > HF most common cause of hospitalization > More hospitalizations for CV disease than COPD > CVD more common cause of death than COPD Denver Health
5. COPD Epidemiology Prevalence: 12.4 - 24 million in US Morbidity: 2004: 461,000 hospitalizations (4 th most common) 1.5 million ED visits Mortality: 120,000 deaths in 2001 (6 th most common - 3 rd by 2020) 1 death/4 min (14 during this lecture) Only cause of death in top 10 that is Cost: $6.5 billion Denver Health
6. COPD Epidemiology: Gender Discrepancy in Mortality Machado, AJRCCM 2006 Mortality for women on O 2 Denver Health
7. COPD Phenotyping Correlates with FEV 1 Health status Resource utilization AECOPD Mortality Small airway wall thickness - Inflammatory cell infiltration - Smooth muscle - Subepithelial fibrosis Does Not Correlate with FEV 1 Emphysema Hyperinflation BMI Peripheral muscle fxn Dyspnea Exercise tolerance Denver Health
8. COPD Phenotyping (courtesy John Riley, B & W) FEV 1 : 105% DL CO : 50% FEV 1 : 95% DL CO : 70% FEV 1 : 40% DL CO : 70% Denver Health
9. COPD Phenotyping: Predictors of Mortality (Multivariate Analysis) 609 pts, NETT, medical Rx Martinez, AJRCCM 2006 Denver Health 1.36 DL CO < 22 1.38 Hemoglobin < 13.4 1.48 Modified BODE 1.40 O 2 use 1.48 Maximum work 1.53 Perfusion ratio 1.56 RV (% predicted) 1.72 Age > 70 1.80 % Upper lobe emphysema Hazard Ratio Predictor
10. COPD Phenotyping: CRP Predicts Hospitalization and Prognosis Hospitalization Death Dahl, AJRCCM 2006 Denver Health
11. COPD Phenotyping: BNP Predicts PHT and Prognosis 176 pts “scheduled for RH cath” BNP Predicts PHT PHT predicts survival BNP predicts survival 85% sensitivity 88% specificity (5% with Ppa > 40 torr) Leuchte, AJRCCM 2006 Denver Health
12. COPD Genetics Candidate Gene Abns SERPINA 1 ( -1-AT) MMP-9 (C-1562 SNP promotor activity) ADAM-33 (adhesion, signaling, proteolysis) Elastin (Gly Asp in terminal exon) Secretory PLA 2 , Group IID CCL1 SNP ( AECOPD x 2 yr) Denver Health
22. AECOPD: Biomarkers Hurst, 2006 Purpose? Dx AECOPD Assess severity Dx other problem Pathobiology Etiology Denver Health
23. AECOPD: Left Heart Dysfunction Abroug, AJRCCM 2006 148 consecutive pts with AECOPD - 55 (37%) on mechanical ventilation All got ECHO, BNP, Troponins Excluded pneumonia, PE, CPA, inotropes ARF, nonechogenic LVF and RVF diagnosed by 4 MDs - Definite, Possible, Unlikely - Clinical data (not BNP or Troponins) Denver Health
24. AECOPD: Left Heart Dysfunction 75 (51%) with LV dysfunction 17 (23%) systolic dysfunction 48 (64%) diastolic dysfunction 10 (13%) both 41 (31%) 20 (14%) 82 (55%) BNP > 1000 94% Sensitive 77% Specific (Abroug, AJRCCM 2006) Denver Health
25. AECOPD: Pulmonary Embolism Spiral CT & US 211 consecutive pts with “unexplained” AECOPD - Not requiring mechanical ventilation - No acute bronchitis, pneumonia, PTX - Disparity between CXR and ABGs 49/197 (25%) positive for PE - 43 by CT (19 of whom had + US) - 6 by US Associations: - Previous PE, malignancy, 5 torr PaCO 2 (Tillie-Leblond, 2006) Denver Health
26. COPD Rx: Steroid Resistance Limited effect of steroids in stable disease Cells, cytokines, proteases in BAL Histology of biopsies IL-8, TNF suppression AM cytokine production Oxidative/nitrative stress inhibits HDAC fxn Denver Health
33. COPD Rx: Long-Acting Bronchodilators GOLD Guidelines Regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting agents Regular use of a long-acting bronchodilator… improves health status Treatment with a long-acting bronchodilator reduces the rate of AECOPD Denver Health
34. COPD Rx: Do LABAs AECOPD? (Sin, JAMA 2003) Denver Health
35. COPD Rx: Does Tiotropium AECOPD? (Sin, JAMA 2003) Denver Health
36. COPD Rx: ICS GOLD Guidelines Regular treatment with ICS is appropriate for symptomatic patients with COPD with an FEV 1 < 50% predicted (stages III and IV) and repeated AECOPD (e.g., 3/3 yr) (Evidence A). This treatment has been shown to reduce AECOPD and thus improve health status (Evidence A) Withdrawal from treatment can lead to AECOPD in some patients. Denver Health
37. COPD Rx: Do ICS AECOPD? Sin, JAMA 2003 Denver Health
38. Effect of Rx on AECOPD (Suissa, AJRCCM 2006) Methods of Analysis Unweighted (individual pt data) (Bad) - AEs for each pt/time of f/u for each pt - Each pt contributes equally regardless of f/u time - Exaggerates Rx effect Weighted (pooled data) (Better) - Total AE for all pts/total time of f/u for all pts - Weights each pt’s AE rate by their f/u time - Produces correct and best estimate (i.e., maximum likelihood estimate) of AE rate (not biased by short f/u) Denver Health
39. Effect of Rx on AECOPD (Suissa, AJRCCM 2006) Analysis of weighted data Assume Poisson distribution for AEs (Bad) - AEs can occur repeatedly, randomly, independently - Ignores that some pts may have frequent AEs and some may have none Estimate variability and use “overdispersion parameter” (Better) - p value and CI based on within- and between- subject variability Denver Health
40. COPD Rx: Quality of the Data Cited supporting references Many used unweighted analyses None used an overdispersion parameter Some analyzed adjusted data One QOL just exceeded “clinically significant” (e.g., 5 vs 4) Many included Pharma employees as authors with analyses performed in-house Some actually reported NO beneficial effects Denver Health
42. COPD Rx: Do ICS AECOPD? Berge (+ Glaxo), BMJ 2000 (ISOLDE) ICS, LABA, ICS + LABA, placebo Analyzed by Glaxo Reported median exacerbation rate # AEs/# Rx days extrapolated to #/yr Unweighted analysis (overestimates effect) Denver Health
43. COPD Rx: Do ICS AECOPD? Van der Valk, AJRCCM 2003 Routine Rx + ICS x 4 M, continue ICS vs P Primary outcome measures - First and second AE - Rapid recurrent AEs - HRQL 21% crossovers 1.3 1.5 vs 1.3 1.6 AEs/yr - 48% had no AEs Time to first AE different (“adjusted for smoking status”) Denver Health
44. COPD Rx: Does Tiotropium AECOPD? Niewoehner, AIM 2005 1829 pts (Mod-Severe) Tiotropium vs usual Rx AECOPD (1 yr): Tiotropium: 28% Placebo: 32% P < 0.05 “ These treatment effects were small to modest, and their overall clinical importance must be weighed against other considerations, including cost” Denver Health
45. COPD Rx: Do ICS AECOPD? Szafranski, ERJ 2003 (126) ICS, LABA, ICS + LABA, placebo Poisson regression, dispersion adjustment Corresponding author @ Astra-Zeneca No correction for multiple comparisons (P < 0.016) Denver Health NS LABA vs Placebo P value Rx NS ICS vs Placebo 0.043 ICS + LABA vs LABA NS ICS + LABA vs ICS 0.035 ICS + LABA vs Placebo
46. COPD Rx: Do ICS Mortality? TORCH study (NEJM 2007) 6100 pts, FEV1 ~ 1.2 L (44%) - Salmeterol - Salmeterol/fluticasone - Fluticasone - Placebo Endpoints: - Death (Primary) - Frequency of AECOPD - QOL (SGRQ) - Lung function Calverley, 2007 Denver Health
47. COPD Rx: Do ICS Mortality? 3-yr mortality: Placebo: 15.2% Combination: 12.6% 17.5% relative P = 0.052 LaVecchia & Fabbri Salmeterol vs not 13 vs 15.6% (P = 0.004) Fluticasone vs not 14.3 vs 14.3% (P = 0.99) Calverley, 2007 Denver Health
48. COPD Rx: Do ICS Mortality? 3-yr COPD mortality: Placebo: 6.0% Combination: 4.7% 21.7% relative P = 0.11 Fluticasone: 6.9% Combination: 4.7% 31.8% relative P = 0.008 LABA vs Combo: NS Calverley,NEJM 2007 Denver Health
49. COPD Rx: Do ICS Mortality? FEV 1 (ml) SGRQ (units) Calverley, NEJM 2007 Denver Health
50. COPD Rx: Do ICS Mortality? Problems: 40% drop out in placebo group (P < 0.05) All pts had indications for Rx Pts with more severe disease might not have enrolled Pneumonia - Placebo: 12.3% - Combination: 19.6% (P < 0.001) - Ernst, AJRCCM 2007: RR 1.70 (1.63-1.77) Rabe, NEJM 2007 Denver Health
51. COPD Rx: Do ICS Mortality? “ All trials are a gamble, and the TORCH investigators came close to winning, but did not win” “ LABA was a winner, ICS was a clear loser” Combination Rx better - Health status - Use of oral steroids - AECOPD - in FEV 1 Combination Rx: severe disease &/or AECOPD (same as GOLD recommendations) More pneumonia in combination Rx Rabe, NEJM 2007 Denver Health